CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 346 participants.

Also called NCT05267886

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 346 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05267886
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05267886. Randomized; triple masking; primary purpose treatment. Start 2022-03-05 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
Acronym
DOREMI-2
Condition
Shock, Cardiogenic
Intervention (Drug)
Dobutamine
Intervention (Drug)
Milrinone
Intervention (Drug)
Normal Saline
Lead sponsor
Ottawa Heart Institute Research Corporation (class: other)

Record details

Record id
cardio:ct-nct05267886
Content hash
545022289f229bda15d38e89240975f6010e160d46d4d121e1466f766cbc6d21